NuVasive(R) Management to Participate in Investor Events in May and June 2013

Marketwired

SAN DIEGO, CA--(Marketwired - May 1, 2013) - NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that management will participate in the following investor events in May and June 2013:

  • Mizuho Securities USA Healthcare Access Day at the Omni Berkshire Place in New York City, New York, on Tuesday, May 7, 2013.

  • BofA Merrill Lynch Healthcare Conference at the Encore at the Wynn Resort in Las Vegas, Nevada, on Tuesday, May 14, 2013, at 8:00 a.m. PDT.

  • William Blair 33rd Annual Growth Stock Conference at the Four Seasons Hotel in Chicago, Illinois, on Wednesday, June, 12, 2013, at 10:00 a.m. CDT.

  • Goldman Sachs 34th Annual Global Healthcare Conference at the Terranea Resort in Rancho Palace Verdes, California, on Wednesday, June 12, 2013, at 10:00 a.m. PDT.

A live webcast of each of the presentations will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, a replay of the presentations will remain available on the website for 30 days.

About NuVasive

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.

NuVasive offers a comprehensive spine portfolio of over 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company places a large focus on clinical research and support of the Society of Lateral Access Surgery, or SOLAS®, to expand the body of clinical evidence in support of NuVasive's minimally disruptive solutions and to drive adoption of its techniques. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-Up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that NuVasive's revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts; the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact:
Investor
Tina Jacobsen
NuVasive, Inc.
858-320-5215
Email Contact

Media
Nicole Collins
NuVasive, Inc.
858-909-1907
Email Contact
View Comments (0)